Bullish & Foolish
Full CPHI fundamentals All 466 on the Survival Watch

CPHICHINA PHARMA HOLDINGS, INC.

Is China Pharma Holdings struggling financially?

Yes, by its own account. China Pharma Holdings told the SEC on 15 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern. It generated cash over the last twelve months rather than burning it, so the doubt here is about something other than an empty bank account.

Going concern disclosed May 2026

30/100

Fragile

Sector
Biotech/Pharma
Market cap
$42.2M
Source filing
10-Q 15 May 2026
Balance sheet
30 Jun 2026

Cash runway

No net burn

This company generated cash over the last twelve months, so there is no burn rate to divide by. Going concern language in this position is usually about debt coming due or a covenant.

What it reported

Cash and short-term investments

$305K

What China Pharma Holdings told the SEC

…Company to make the required payments related to its former construction loan facility and current lines of credit. To alleviate the conditions that raise substantial doubt about the Company’s ability to continue as a going concern, management plans to enhance the sales model of advance payment, and further strengthen its collection of accounts receivable. Further, the Company is currently exploring strategic…

CHINA PHARMA HOLDINGS, INC., Form 10-Q, filed 15 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 945.0% share-count increase The company issued stock. Each share now owns 90.4% less of the business than a year ago, before any change in the price.
  • Debt pressure is material Operating earnings cover only -136.4x the interest bill, so the interest is being met out of cash reserves rather than out of the business.

Other Biotech/Pharma companies that filed the doubt